Growth Capital, Llc Investor Net Worth

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Growth Investor STIM stock SEC Form 4 insiders trading

Growth has made over 1 trades of the Neuronetics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Growth bought 118,187 units of STIM stock worth $354,561 on 23 February 2017.

The largest trade Growth's ever made was buying 118,187 units of Neuronetics Inc stock on 23 February 2017 worth over $354,561. On average, Growth trades about 39,396 units every 0 days since 2017. As of 23 February 2017 Growth still owns at least 2,838,557 units of Neuronetics Inc stock.

You can see the complete history of Growth Investor stock trades at the bottom of the page.

What's Growth Investor's mailing address?

Growth's mailing address filed with the SEC is C/O PATRICIA INDUSTRIES, 1177 AVENUE OF THE AMERICAS, 47TH FLOOR, NEW YORK, NY, 10036.

Insiders trading at Neuronetics Inc

Over the last 6 years, insiders at Neuronetics Inc have traded over $9,582,393 worth of Neuronetics Inc stock and bought 1,499,267 units worth $4,708,316 . The most active insiders traders include Capital Llc Cannell, Ronald Hunt, and Glenn P Muir. On average, Neuronetics Inc executives and independent directors trade stock every 20 days with the average trade being worth of $21,199. The most recent stock trade was executed by Glenn P Muir on 5 September 2024, trading 25,000 units of STIM stock currently worth $20,000.

What does Neuronetics Inc do?

with neurostar advanced therapy, neuronetics, inc., is the market leader in transcranial magnetic stimulation technology for the treatment of major depressive disorder. based in malvern, pa, we are a privately held medical device company focused on developing non-invasive therapies for psychiatric and neurological disorders using mri-strength magnetic field pulses. we are the first company to have a non-systemic and non-invasive depression treatment cleared by the fda for patients who have not benefited from prior antidepressant medication. neuronetics markets neurostar advanced therapy throughout the united states and select markets around the world. if you have questions or comments about neurostar, please e-mail us at customersupport@neuronetics.com. for u.s. phone support, please call us at (877) 600-7555, for international customers, our number is +1 (610) 640-4207.

Neuronetics Inc executives and stock owners

Neuronetics Inc executives and other stock owners filed with the SEC include:

• Daniel Guthrie,
  Chief Commercial Officer
• Stephen Furlong,
  Vice President, Chief Financial Officer, Office of the President
• Gregory Harper,
  Vice President - Product Development and Operations
• Keith J. Sullivan,
  Pres, CEO & Director
• Yelena Tropsha,
  Vice President - Commercial Access
• Stephen J. Furlong M.S.,
  Sr. VP, CFO & Treasurer
• W. Andrew Macan,
  Sr. VP, Gen. Counsel, Chief Compliance Officer, Sec. & Member of Office of the Pres
• Brian Farley,
  Independent Non-Executive Chairman of the Board
• Glenn Muir,
  Independent Director
• Wilfred Jaeger,
  Independent Director
• Sheryl Conley,
  Independent Director
• Mark Klausner,
  Managing Partner
• Bruce Shook,
  Independent Director
• John Bakewell,
  Director
• Sara Grubbs,
  Vice President of Sales
• W. Andrew Macan,
  Senior Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary, Office of the President
• Keith Sullivan,
  President, Chief Executive Officer, Director
• Kara Thornton,
  VP of HR & Sr. Director
• Claire Sears,
  VP of Marketing
• Leaf Ventures Ii, L.P.New L...,
  
• Paulina Hill,
  Director
• Stephen M Campe,
  Director
• Ventures Ltd General Electr...,
  
• Ronald Hunt,
  Director
• Growth Capital, Llc Investor,
  10% owner
• Megan Rosengarten,
  
• Christopher Thatcher,
  President and CEO
• Peter Donato,
  Vice President and CFO
• Cheryl R Blanchard,
  Director
• Capital Llc Cannell,
  10% owner
• Joseph H Capper,
  Director
• Robert Cascella,